Indeed, we demonstrated that active kinase candidates are discovered from the deep phosphop- and pY proteomic data (Table 1) and that the Src family kinases, SRC, and YES1 are potential druggable targets in colorectal cancer resistant to Cetuximab as shown in Fig. 5b. This evidence concerns the gene YES1 and colorectal cancer.